Haematologica, Vol 92, Issue 10, 1343-1350 doi:10.3324/haematol.11523
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Valsami, S.
Right arrow Articles by Economopoulos, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Valsami, S.
Right arrow Articles by Economopoulos, T.

Malignant Lymphomas

A clinicopathological study of B-cell differentiation markers and transcription factors in classical Hodgkin’s lymphoma: a potential prognostic role of MUM1/IRF4

Serena Valsami, Vassiliki Pappa, Dimitra Rontogianni, Frieda Kontsioti, Efstathios Papageorgiou, John Dervenoulas, Themis Karmiris, Sotirios Papageorgiou, Nikolaos Harhalakis, Nikolaos Xiros, Emmanuel Nikiforakis, Theofanis Economopoulos

From the Second Department of Internal Medicine, Attikon University General Hospital, Haidari, Athens, Greece (SV, VP, FK, EP, JD, SP, NX, TE); Pathology Department, Evangelismos Hospital, Athens, Greece (DR); Department of Hematology-Lymphomas, Evangelismos, Athens, Greece (TK, NH, EN)

Correspondence: Serena Valsami, MD, Second Department of Internal Medicine, Attikon University General Hospital, 1 Rimini Street, 12462 Haidari, Athens, Greece. E-mail: serenavalsami{at}yahoo.com

Background and Objectives: Although most patients with classical Hodgkin’s lymphoma (CHL) are cured, a significant minority are refractory to treatment. The investigation of biological markers could improve the predictive capacity of clinical staging systems. The aim of our study was to detect B-cell differentiation markers and transcription factors in CHL in order to define subgroups with different histogeneses and prognoses.

Design and Methods: We evaluated 107 cases of CHL for BCL6, CD79a, MUM1/IRF4 and B-cell transcription factors BOB.1, OCT.2 expression by immunohistochemistry. Statistical analysis was performed using Fisher’s exact test, the Mann-Whitney test, the Kaplan-Meier method and the log rank test. Univariate and multivariate regression analyses were performed to identify variables with a significant effect on survival.

Results: CD79a was expressed in 5.8%, BCL6 in 14.7%, MUM1/IRF4 in 92.3%, BOB.1 in 53.4% and OCT.2 in 12.6% of cases. There was no significant association between CD79a or BCL6 expression and clinical characteristics. Univariate analysis showed that age of 45 or more, stage III and IV disease and MUM/IRF4 negative status were associated with significantly shorter time to progression (TTP) and overall survival (OS). On multivariate analysis the lack of MUM/IRF4 expression was associated with significantly shorter TTP while age of 45 or more and the presence of extralymphatic sites of disease were associated with significantly shorter OS.

Interpretation and Conclusions: Our study has confirmed that MUM1/IRF4 is expressed in most cases of CHL and shows that lack of this expression in a minority of cases may be a potential adverse prognostic factor.

Key words: classical Hodgkin’s lymphoma, immunohistochemistry, MUM1/IRF4, prognostic factors, survival.